CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$3.23
0.02 (0.47%)
â˛
5d:
-3.44%
30d:
-0.46%
90d:
+16.85%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -5.3% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -5.3% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $3.23, which is considered slightly low relative to its 30-day fair value range of $3.21 to $3.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.8) compared to its historical average (21.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.3% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $3.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.47. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $3.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.47. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.21 -
$3.42
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
Protect Your Profits
Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 23.5% above Wall St target ($2.47)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.21 -
$3.42
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.19
Resistance Level
$3.46
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.82
Wall Street Target
$2.47
(-23.5%)
Revenue Growth (YoY)
58.4%
Earnings Growth (YoY)
126.8%
Profit Margin
39.1%
Valuation Discount vs History
-5.3% cheaper
PE vs Historical
17.8 vs 21.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.3%
(market-implied from PE analysis)
1-Year Target
$3.05
(-5%)
2-Year Target
$2.89
(-10%)
3-Year Target
$2.74
(-15%)
3-Yr Target (if PE normalizes)
(PE: 18â21)
$3.23
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: -18.8%)
$2.69
(+-17%)
Base:
(SPY PE: 17.8, Growth: -18.8%)
$2.35
(-27%)
Bear:
(PE: 15.1, Growth: -18.8%)
$2.00
(-38%)
đ
Valuation based on Current Earnings
Trailing PE: 16.89 | Current EPS (TTM): $0.19
Bull Case
$3.36
(+4%)
Analyst growth -4.7%, PE expands to 18.6
Base Case
$3.06
(-5%)
Market implied -4.7%, PE stable at 16.9
Bear Case
$2.18
(-32%)
Severe decline -20.0%, PE contracts to 14.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.8 to 21.0
Stabilization Target:
$3.80
(+17.9%)
PE Expansion Potential:
+17.9%
Share & Embed Analysis
Last updated: October 03, 2026 6:29 PM ET
Data refreshes hourly during market hours. Next update: 7:29 PM
Data refreshes hourly during market hours. Next update: 7:29 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
